1 Department of Clinical Laboratory, Taian Central Hospital, Taian 271000, China.
2 Department of Public Health, Taishan Medical University, Taian 271000, China.
Exp Biol Med (Maywood). 2019 Sep;244(12):983-991. doi: 10.1177/1535370219861928. Epub 2019 Jul 12.
Primary liver cancer is a major public health challenge that ranks as the third most common cause of cancer worldwide despite therapeutic improvement. Reovirus has been emerging as a potential anti-cancer agent and is undergoing multiple clinical trials, and it is reported that reovirus can preferentially cause the cell death of a variety of cancers in a manner of apoptosis. As few studies have reported the efficacy of oncolytic activity and safety profile of avian reovirus, in our study, LDH assay, MTT assay, DAPI staining, and flow cytometry assay were performed to demonstrate the oncolytic effects of avian reovirus against the HepG2 cells, and quantitative real-time PCR (qRT-PCR) and animal experiments were conducted to investigate the dynamic distribution of avian reovirus in infected mice and then illustrate the safety and tissue tropism of avian reovirus. LDH assay, DAPI staining, and flow cytometry assay confirmed the efficacy of the oncotherapeutic effects of avian reovirus, and MTT assay has indicated that avian reovirus suppressed the proliferation of HepG2 cells and decreased their viability significantly. qRT-PCR revealed the dynamic distribution of avian reovirus in infected mice that avian reovirus might replicate better and have more powerful oncolytic activity in liver, kidney, and spleen tissues. Furthermore, histopathological examination clearly supported that avian reovirus appeared non-pathogenic to the normal host, so our study may provide the new insights and rationale for the new strategy of removing liver cancer.
We demonstrated the efficacy of oncolytic activity of avian reovirus (ARV) by LDH assay, MTT assay, DAPI staining, and flow cytometry assay, and also investigated the dynamic distribution of ARV in infected mice and then illustrated the safety and tissue tropism of ARV by quantitative real-time PCR (qRT-PCR) and animal experiments. Collectively, our study may provide the new insights and rationale for the new strategy of removing liver cancer.
原发性肝癌是一项重大的公共卫生挑战，尽管治疗有所改善，但它仍是全球第三大常见癌症病因。呼肠孤病毒已成为一种有潜力的抗癌药物，并正在进行多项临床试验，据报道呼肠孤病毒可以通过细胞凋亡的方式优先导致多种癌症的细胞死亡。由于很少有研究报告禽呼肠孤病毒的抗肿瘤活性和安全性，在我们的研究中，通过 LDH 检测、MTT 检测、DAPI 染色和流式细胞术检测来证明禽呼肠孤病毒对 HepG2 细胞的溶瘤作用，并且通过定量实时 PCR（qRT-PCR）和动物实验来研究感染小鼠中禽呼肠孤病毒的动态分布，进而阐明禽呼肠孤病毒的安全性和组织趋向性。LDH 检测、DAPI 染色和流式细胞术检测证实了禽呼肠孤病毒的抗肿瘤治疗效果，MTT 检测表明禽呼肠孤病毒抑制了 HepG2 细胞的增殖并显著降低了其活力。qRT-PCR 揭示了感染小鼠中禽呼肠孤病毒的动态分布，表明禽呼肠孤病毒在肝脏、肾脏和脾脏组织中可能更好地复制并具有更强的溶瘤活性。此外，组织病理学检查清楚地表明禽呼肠孤病毒对正常宿主没有致病性，因此我们的研究可能为去除肝癌的新策略提供新的见解和依据。
我们通过 LDH 检测、MTT 检测、DAPI 染色和流式细胞术检测来证明禽呼肠孤病毒（ARV）的溶瘤活性，通过定量实时 PCR（qRT-PCR）和动物实验来研究 ARV 在感染小鼠中的动态分布，并进一步通过动物实验来阐明 ARV 的安全性和组织趋向性。总的来说，我们的研究可能为去除肝癌的新策略提供新的见解和依据。
